NEW: Inotuzumab ozogamicin with or without blinatumomab added to low-intensity chemotherapy showed promising activity in terms of PFS in older patients with B-cell ALL: results of a phase 2 trial
Source: The Lancet Haematology/Twitter
NEW: Inotuzumab ozogamicin with or without blinatumomab added to low-intensity chemotherapy showed promising activity in terms of PFS in older patients with B-cell ALL: results of a phase 2 trial
Source: The Lancet Haematology/Twitter